Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021) - PubMed

Review

Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021)

Patrik Oleksak et al. Eur J Med Chem. 2022.

Abstract

Mechanistic target of rapamycin (mTOR) is a highly conserved protein kinase acting as a central regulator of cell functions. The kinase forms two distinct mTOR complexes termed as mTORC1 and mTORC2. Dysregulation of mTOR activity is associated with various pathological conditions. Inhibition of overactivated mTOR represent a rational approach in the treatment of numerous human diseases. Rapamycin is a potent natural inhibitor of mTOR exhibiting significant antitumor and immunosuppressive activity. Derivatization of rapamycin provided rapalogs, the first generation of mTOR inhibitors that selectively inhibit mTORC1 activity. Further interest of research community resulted in creation of the second generation of mTOR inhibitors involving both, mTOR kinase inhibitors and dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitors. Recently, combining advances of first and second generation of mTOR inhibitors yielded in the third generation of inhibitors termed as rapalinks. Nowadays, novel inhibitors belonging to all of the three generations are still under development. These inhibitors help us better to understand role of mTOR in mTOR signaling pathway as well as in diverse human diseases. In this review, we summarize recent reported mTOR inhibitors or methods of use thereof in the treatment of various diseases.

Keywords: Dual PI3K/mTOR inhibitors; PI3K/AKT/mTOR signaling pathway; Rapalinks; Rapalogs; Rapamycin; mTOR inhibitor; mTOR kinase inhibitors.

Similar articles

• New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

  Feldman ME, Shokat KM. Feldman ME, et al. Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.

• Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

  Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Feldman ME, et al. PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038. PLoS Biol. 2009. PMID: 19209957 Free PMC article.

• Current development of the second generation of mTOR inhibitors as anticancer agents.

  Zhou HY, Huang SL. Zhou HY, et al. Chin J Cancer. 2012 Jan;31(1):8-18. doi: 10.5732/cjc.011.10281. Epub 2011 Nov 4. Chin J Cancer. 2012. PMID: 22059905 Free PMC article. Review.

• Overview of Research into mTOR Inhibitors.

  Mao B, Zhang Q, Ma L, Zhao DS, Zhao P, Yan P. Mao B, et al. Molecules. 2022 Aug 19;27(16):5295. doi: 10.3390/molecules27165295. Molecules. 2022. PMID: 36014530 Free PMC article. Review.

• Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

  Fan QW, Weiss WA. Fan QW, et al. Methods Mol Biol. 2012;821:349-59. doi: 10.1007/978-1-61779-430-8_22. Methods Mol Biol. 2012. PMID: 22125077 Free PMC article.

Cited by

• Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies.

  Zheng L, He S, Wang H, Li J, Liu Y, Liu S. Zheng L, et al. Aging Dis. 2024 Feb 27;15(6):2554-2594. doi: 10.14336/AD.2024.0206. Aging Dis. 2024. PMID: 38421832 Free PMC article. Review.

• Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy.

  Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani MM, Al Awadh AA, Benali T, Lee LH, El Omari N, Goh KW, Ming LC, Mubarak MS. Bouyahya A, et al. Cancers (Basel). 2022 Nov 10;14(22):5520. doi: 10.3390/cancers14225520. Cancers (Basel). 2022. PMID: 36428613 Free PMC article. Review.

• Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics.

  Chrienova Z, Rysanek D, Oleksak P, Stary D, Bajda M, Reinis M, Mikyskova R, Novotny O, Andrys R, Skarka A, Vasicova P, Novak J, Valis M, Kuca K, Hodny Z, Nepovimova E. Chrienova Z, et al. Front Aging Neurosci. 2022 Dec 6;14:1048260. doi: 10.3389/fnagi.2022.1048260. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36561137 Free PMC article.

• Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson's Disease.

  Kinet R, Dehay B. Kinet R, et al. Cells. 2023 Feb 15;12(4):621. doi: 10.3390/cells12040621. Cells. 2023. PMID: 36831288 Free PMC article. Review.

• The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization.

  Liu Y, Zhang M, Jang H, Nussinov R. Liu Y, et al. Chem Sci. 2023 Dec 7;15(3):1003-1017. doi: 10.1039/d3sc04690g. eCollection 2024 Jan 17. Chem Sci. 2023. PMID: 38239681 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Chemical Information

  • BindingDB

• Miscellaneous

  • NCI CPTAC Assay Portal